At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Jun 5, 2026 at 08:01 ET
Taysha Gene Therapies granted 714,700 RSUs and an option for 468,600 shares to four new employees under its 2023 Inducement Plan, with a $5.97 exercise price. This is a routine equity inducement grant for new hires, not a material operational or financial event.
- 714,700 RSUs and an option for 468,600 shares granted to four new employees on June 1, 2026
- Stock option exercise price set at $5.97, equal to the closing price on grant date
- RSUs vest in four equal annual installments; option vests 25% on first anniversary, then monthly over 36 months
- Grant made under the 2023 Inducement Plan per Nasdaq Listing Rule 5635(c)(4)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access